Advanced search
Publication Cover
Pathogens and Global Health Volume 107, 2013 - Issue 8: Molecular and Population Biology of Mosquitoes and Other Disease Vectors
Submit an article Journal homepage
1,539
Views
25
CrossRef citations to date
0
Altmetric
Special Issue Article

Malaria caused by Plasmodium vivax: recurrent, difficult to treat, disabling, and threatening to life — averting the infectious bite preempts these hazards

J. Kevin BairdEijkman-Oxford Clinical Research UnitJakarta, Indonesia;The Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, UKCorrespondence[email protected]
Pages 475-479 | Published online: 15 Jan 2014

References

  • Gething PV, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, . A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012;6:e1814.
  • Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007;77(Suppl 6):79–87.
  • World Health Organization. World malaria report 2007. Geneva: World Health Organization; 2008.
  • Hay SI, Okiro EA, Gething PW, Patil AP, Tatem AJ, Guerra CA, . Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med. 2010;7:e1000290.
  • Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013;26:36–57.
  • White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malaria J. 2011;10:297.
  • Ehrman FC, Ellis JM, Young MD. Plasmodium vivax Chesson strain. Science. 1945;101:377.
  • Garnham PC, Bray RS, Bruce-Chwatt LJ, Draper CC, Killick-Kendrick R, Sergiev PG, . A strain of Plasmodium vivax characterized by prolonged incubation: morphological and biological characteristics. Bull WHO. 1975;52:21–32
  • Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, . Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis. 2011;52:612–20.
  • Downs WG, Harper PA, Lisansky ET. Malaria and other insect-borne diseases in the South Pacific campaign. II. Epidemiology of insect borne diseases in Army troops. Am J Trop Med. 1947;27:69–89.
  • Ohrt C, Richie TL, Widjaja H, Shanks GD, Fitriadi J, Fryauff DJ, . Mefloquine compared to doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126:963–72.
  • Lança EF, Magalhaes BM, Vitor-Silva S, Siqueira AM, Benzecry SG, Alexandre MA, . Risk factors and characterization of Plasmodium vivax-associated admissions to pediatric intensive care units in the Brazilian Amazon. PLoS ONE. 2012;7:e35406.
  • World Health Organization. Management of severe malaria. A practical handbook. 3rd ed. Geneva: World Health Organization; 2012.
  • Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev. 2009;22:508–34.
  • Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Inf Dis. 2010;10:405–16.
  • Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, . Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother. 2013;57:1128–35.
  • Cappellini MD, Fiorelli G. Glucos-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64–74.
  • Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, . G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339.
  • von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, . Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malaria J. 2013;10.1186.
  • Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, . Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013;369:1381–2.
  • Wojtczak A, Rychlik-Sych M, Krochmalska-Ulacha E, Skretkowicz J. CYP2D6 phenotyping with dextromethorphan. Pharmacol Rep. 2007;59:734–8.
  • Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, . Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis. 2009;48:1704–12.
  • Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Warikar N, Seal A, . Adverse pregnancy outcomes in an area where multi-drug resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis. 2008;46:1374–81.
  • Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, . The anaemia of Plasmodium vivax malaria. Malaria J. 2012;11:135.
  • McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M, . Adverse effects of falciparum and vivax malaria and the safety of antimalarial drug treatment in early pregnancy: a population-based study. Lancet Infect Dis. 2012;12:388–96.
  • World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization, 2010.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.